Professor of Obstetrics and Gynecology, UCSD
Obstetrics & Gynecology
Dr. Steven C. Plaxe, MD
|
|
Give Review
Steven C. Plaxe, MD practices Obstetrics & Gynecology. He studied medicine at Icahn School of Medicine at Mount Sinai. Icahn School of Medicine at Mount Sinai has a rank of 20 in research and a 62 in primary care He received 8 awards: "America's Top Doctors", "Top Doctors:San Diego Area", "America's Top Doctors for Cancer", "Top Doctors:Southern California", "CMS Meaningful Use Stage 1 Certification", "Fellow (FACS)", "Super Doctor" and "Fellow (FACOG)". Steven Plaxe is a published physician. He has 53 publications published. The most current publication "Phase I and pharmacokinetic study of intraperitoneal topotecan." Steven Plaxe accepts Medicare payments and is listed with Medicare.gov.
Publications
- Bariatric surgery decreases the risk of Uterine malignancy.
- The risk of uterine malignancy is linearly Associated with body mass index in a cohort of US women.
- Regional variation in surgical assessment of lymph nodes for staging among women with early-stage epithelial ovarian Cancer.
- Excess risk of Clostridium difficile infection in ovarian Cancer is related to exposure to broad-spectrum antibiotics.
- Use of psychosocial services increases after a social worker-mediated intervention in gynecology oncology patients.
- Women with gynecologic malignancies have a greater incidence of suicide than women with other Cancer types.
- Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian Carcinoma cell growth and tumor progression.
- Endometrioid Carcinoma with a low-grade spindle cell component: a tumor resembling an adnexal tumor of probable Wolffian origin.
- Primary squamous Carcinoma of the ovary likely arising from a monodermal cystic mucinous teratoma.
- Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent Cervical cancer: a pooled analysis of 3 Gyneco...
- Epidemiology of low-grade serous ovarian Cancer.
- Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial Carcinoma: a Gynecologic Oncology Group Study.
- Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian Cancer: a Gynecologic Oncology Group study.
- Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian Cancer.
- Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian Cancer: a Gynecologic Oncology Group study.
- A phase II trial of pyrazoloacridine (PZA) in squamous cell Carcinoma of the cervix: a Gynecologic Oncology Group study.
- Pharmacokinetic study of intraperitoneal streptozotocin.
- Induction chemotherapy followed by radical surgery in Cervical cancer.
- A phase II trial of adjuvant cisplatin and doxorubicin in stage I epithelial ovarian Cancer.
- Intraperitoneal cisplatin-based chemotherapy for ovarian Carcinoma.
- Phase I and pharmacokinetic trial of intraperitoneal etoposide in combination With the multidrug-resistance-modulating agent dipyridamole.
- Clinical features of advanced ovarian mixed mesodermal tumors and treatment With doxorubicin- and cis-platinum-based chemotherapy.
- Ovarian intraepithelial neoplasia demonstrated in patients with stage I ovarian Carcinoma.
- Clinical features and treatment outcome of patients with epithelial Carcinoma of the ovary metastatic to the central nervous system.
- A comparative study of computerized tomography, magnetic resonance imaging, and clinical staging for the detection of early cervix Cancer.
- Therapeutic and metabolic effects of high (greater than 1 g/m2) systemic cumulative doses of cis-platinum in patients with ovarian Carcinoma.
- Extrauterine Pelvic malignant mixed mesodermal tumors. A study of 10 cases with immunohistochemistry.
- In utero exchange transfusion by direct intravascular injection in severe erythroblastosis fetalis.
- Routine clinical chemistries as improved determinates of prognosis for patients with metastatic Cancer of the stomach.
- Studies in prognostic factors relating to chemotherapy for advanced gastric Cancer.
- Absolute granulocyte, lymphocyte, and moncyte counts. Useful determinants of prognosis for patients with metastatic Cancer of the stomach.
- A phase II trial of intraperitoneal high-dose carboplatin and etoposide with granulocyte macrophage-colony stimulating factor support in patients with ovarian Carcinoma.
- Phase I trial of cisplatin in combination With glutathione.
- A phase I trial of intraperitoneal carboplatin and etoposide With granulocyte macrophage colony stimulating factor support in patients With intraabdominal malignancies.
- A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian Cancer.
- Phase I and pharmacokinetic study of intraperitoneal ormaplatin.
- Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin.
- High-dose biweekly intraperitoneal cisplatin: an effective way to increase cisplatin dose intensity.
- A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide.
- Gynecologic malignancy presenting as hernia.
- A simplified approach to superficial inguinal dissection with sparing of the saphenous vein in patients with Carcinoma of the vulva.
- Profiles of women age 30-39 and age less than 30 with epithelial ovarian Cancer.
- Dose intensification of cisplatin chemotherapy through biweekly administration.
- Impact of ethnicity on the incidence of high-risk endometrial Carcinoma.
- Endometrioid ovarian Carcinoma in a premenarchal girl: report of a case.
- Field Cancerization: why late "recurrent" ovarian Cancer is not recurrent.
- Phase I and pharmacokinetic study of intraperitoneal topotecan.
- TransCervical metallic stents for drainage of uterine collections.
- A phase II/pharmacokinetic trial of high-dose progesterone in combination With paclitaxel.
- Estimation of the duration of the preclinical phase of cervical adenoCarcinoma suggests that there is ample opportunity for screening.
- Increase in tumor GADD153 mRNA level following treatment correlates With response to paclitaxel.
- A phase II trial of pyrazoloacridine (PZA) in squamous Carcinoma of the cervix--a Gynecologic Oncology Group Study.
Schools
Mount Sinai School of Medicine
Yale New Haven Hospital
Mt Sinai School Med
Procedures Preformed
- Abdominal Hysterectomy With Robotic Assistance
- Colposcopy
- Destruction or Excision of Lesion of Cervix (incl. LEEP)
- EndoCervical Curettage
- View All
Conditions Treated
- Atrophic Vaginitis
- Carcinoma in Situ
- Cervical Cancer
- Cervical Polyps
- View All
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Power Select HMO
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Tiered Direct Access
- Select Plus HMO
- Cigna HMO
- Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- Federal Employee Program (FEP)
- Medicare Advantage PFFS
- Humana
- Kaiser Permanente
- Medicaid
- Medicare MCR
- Molina
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- MVP Health Care
- Heritage Signature
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- PacifiCare HMO
- United Healthcare
Awards
- America's Top Doctors
- Top Doctors:San Diego Area
- America's Top Doctors for Cancer
- Top Doctors:Southern California
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACS)
- Super Doctor
- Fellow (FACOG)
Education
-
Mount Sinai School of Medicine -
Yale New Haven Children's Center -
Yale-New Haven Hospital -
Icahn School of Medicine at Mount Sinai
Hospital
-
UC San Diego Health
Drug Facts
| NPI NUMBER | 1942356795 | |
| NPPES Provider LastName | PLAXE | |
| NPPES Provider FirstName | STEVEN | |
| NPPES Provider ZIPCode | 921038201 | |
| NPPES Provider State | CA | |
| Specialty Description | Gynecological/Oncology | |
| Total Claim Count | 28.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1942356795 |
| Last Name Of The Provider | PLAXE |
| First Name Of The Provider | STEVEN |
| View All |
Similar Doctors
|
|
Dr. Seth D. Bulow, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harold A. Beck, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mel M. Kurtulus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David B. Smotrich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael B. Silverman, MD |
|
|
Dr. Erin A. Gross, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Catherine A. Buerchner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cheryl C. Saenz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vivian E. Ellis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Manuel A. Doblado, MD
This Doctor is OpenDoctor Recommended.
|